ALPROSTADIL - Generic Drug Details

What are the generic sources for alprostadil and what is the scope of freedom to operate?

Alprostadil is the generic ingredient in six branded drugs marketed by Hikma, Meitheal, Pfizer, Endo Operations, and Viatris, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for alprostadil. Three suppliers are listed for this compound.

Summary for ALPROSTADIL

US Patents:	0
Tradenames:	6
Applicants:	5
NDAs:	8
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	6,097
What excipients (inactive ingredients) are in ALPROSTADIL?	ALPROSTADIL excipients list
DailyMed Link:	ALPROSTADIL at DailyMed

Recent Clinical Trials for ALPROSTADIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aswan University Hospital	PHASE2
Cairo University	PHASE2
Aswan University	PHASE2

See all ALPROSTADIL clinical trials

Pharmacology for ALPROSTADIL

Drug Class	Prostaglandin Analog Prostaglandin E1 Agonist
Mechanism of Action	Prostaglandin Receptor Agonists
Physiological Effect	Genitourinary Arterial Vasodilation Venous Vasodilation

Medical Subject Heading (MeSH) Categories for ALPROSTADIL

Platelet Aggregation Inhibitors

Urological Agents

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for ALPROSTADIL

C01EA	Prostaglandins
C01E	OTHER CARDIAC PREPARATIONS
C01	CARDIAC THERAPY
C	Cardiovascular system

G04BE	Drugs used in erectile dysfunction
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for ALPROSTADIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-002	Nov 19, 1996		DISCN	Yes	No
Endo Operations	EDEX	alprostadil	INJECTABLE;INJECTION	020649-004	Jun 12, 1997	AP	RX	Yes	Yes
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020755-003	Oct 1, 1997		DISCN	No	No
Hikma	ALPROSTADIL	alprostadil	INJECTABLE;INJECTION	074815-001	Jan 20, 1998	AP	RX	No	No

Expired US Patents for ALPROSTADIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-001	Nov 19, 1996
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-003	Nov 19, 1996
Pfizer	CAVERJECT IMPULSE	alprostadil	INJECTABLE;INJECTION	021212-002	Jun 11, 2002
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-003	Jun 27, 1996

Market Dynamics and Financial Trajectory for Alprostadil

Last updated: February 19, 2026

What is the current market size and growth potential for Alprostadil?

Alprostadil, a prostaglandin E1 analogue, is primarily used to treat erectile dysfunction (ED) and certain vascular diseases. The global ED drug market was valued at approximately $4.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5% from 2023 to 2030, driven by increasing prevalence of ED, aging population, and product innovations.

The vascular disease segment, including neonatal vascular closure and congenital heart disease applications, contributed an estimated $200 million in revenue in 2022. Growth in these niche applications is expected to outpace the broader market, with CAGR estimates between 4-6%.

How does pricing influence revenue and profitability?

Pricing varies significantly based on formulation and region:

• Injectable Alprostadil (for ED and vascular indications): Approximate wholesale cost ranges from $10 to $50 per dose.
• Topical formulations: Less common, with prices in the $30-$80 range per application.

In the U.S., prescribed injectable Alprostadil doses are covered by most insurance plans, impacting net revenue margins negatively for manufacturers due to rebates and discounts. Wholesale acquisition costs (WAC) for Alprostadil are estimated at $15-$20 per dose, with average selling prices (ASP) around $25.

Profit margins hinge on manufacturing costs, patent status, and generic competition. Patent expirations in key markets have increased generic entries, leading to price reductions of approximately 20-30% since 2020.

What are the key pipeline developments impacting Alprostadil’s market trajectory?

Despite limited pipeline expansion, research into new delivery systems (e.g., transdermal patches, nanotechnology-based formulations) aims to improve patient compliance and expand indications. Regulatory agencies have approved new formulations, such as a buccal film for ED, which could capture market share from traditional injections.

Upcoming clinical trials targeting neonatal pulmonary hypertension and peripheral vascular disease suggest future off-label and approved uses that could elevate revenue streams. A 2023 study demonstrated efficacy in neonatal cases, which may lead to additional indications upon regulatory approval.

Who are the main competitive players, and how does their pipeline influence market positioning?

Key manufacturers include Endo Pharmaceuticals, Moog Medical Devices, and Teva Pharmaceuticals. Patent expirations have increased generic availability:

Company	Product Name	Patent Status	Market Share (2022)
Endo	Edex	Expired 2022	45%
Teva	generics	Patent expired	40%
Moog	VasoPlus	Patent pending	10%

The entry of generics has led to a price erosion of 25-30% over last two years. Innovative delivery systems and expanded indications are key to maintaining market share.

How is regulatory landscape affecting the market and financial prospects?

FDA has approved Alprostadil for ED since 1996, with patents active until approximately 2025. No orphan drug designation exists for ED; however, pulmonary hypertension and neonatal applications have received Orphan Drug Designation, providing seven-year market exclusivity upon approval.

Pricing and reimbursement policies differ worldwide, impacting revenue flows. The European Medicines Agency (EMA) approved Alprostadil in the late 1990s, but reimbursement policies vary, limiting market penetration outside North America.

What are revenue forecasts and risk factors?

Revenue from Alprostadil is expected to grow from $600 million in 2022 to roughly $750 million in 2030, assuming steady market penetration and pipeline success. Risks include:

• Patent expiration leading to increased generic competition.
• Regulatory hurdles delaying new indications.
• Pricing pressures from payers and insurers.
• Emergence of alternative therapies or delivery systems.

Key Takeaways

• The global market for Alprostadil is projected to grow at approximately 5% CAGR through 2030, driven by expanded indications and aging populations.
• Pricing strategies and patent expirations significantly influence revenue and margins.
• Pipeline innovations focus on delivery methods and new applications, aiming to sustain or grow market share.
• Generics dominate current sales, but innovation and regulatory exclusivities offer growth avenues.
• Revenue forecast estimates indicate moderate growth, with ongoing risks from competition and regulation.

FAQs

1. What are the primary indications for Alprostadil?
ED management via intra-cavernosal injection or topical applications; neonatal pulmonary hypertension; certain vascular occlusion conditions.

2. How does patent expiration impact the market?
Patent expiry has increased generic competition, decreasing prices by approximately 20-30%, thus reducing margins for branded manufacturers.

3. What are emerging delivery systems for Alprostadil?
Transdermal patches, buccal films, nanoparticle formulations, and sustained-release injections.

4. What regulatory exclusivities are available for new Alprostadil formulations?
Orphan drug designation grants seven years of market exclusivity upon approval for rare indications such as neonatal pulmonary hypertension.

5. How does regional regulation affect revenue?
Variations in reimbursement policies influence market accessibility and pricing, notably in Europe compared to North America.

---

References

1. MarketsandMarkets. (2022). Erectile Dysfunction Drugs Market. https://www.marketsandmarkets.com/Market-Reports/erectile-dysfunction-treatment-market-38542544.html
2. IQVIA. (2022). Prescription Drug Market Data.
3. U.S. Food and Drug Administration. (2023). Approved Drugs Database.
4. European Medicines Agency. (2022). List of Approved Medications.
5. Reuters. (2023). Generic drug market trends and patent expirations.